

NextCell supports ProTrans study for children and adolescents

NextCell Pharma AB (“NextCell”) has entered into an agreement with Professor Per-Ola Carlsson, at Uppsala University Hospital and Uppsala University, with the aim of contributing the stem cell product ProTrans™ (ProTrans) for the treatment of children and adolescents with type 1 diabetes, within the framework of clinical drug trials. The study, which is in the planning stage, is part of NextCell's strategy to support academic groups with drugs to be able to evaluate ProTrans for a wider use.

NextCell's drug candidate, ProTrans, for the treatment of type 1 diabetes is a mesenchymal stem cell treatment that prevents the breakdown of the insulin-producing beta cells. ProTrans has shown a protective effect in both phase 1 and 2 studies without giving any serious side effects, evaluated in the ProTrans-1 and ProTrans-2 studies. For safety reasons, only adult patients have been treated, although it is more common to be diagnosed with type 1 diabetes at the age of 10-12.

Professor Per-Ola Carlsson is the principal investigator for all NextCell's clinical trials with ProTrans for the treatment of type 1 diabetes and will also be the principal investigator in the planned phase III study ProTrans-3. In addition, he intends, with his own research grants, to apply for and carry out a first study with children and young people, something he presented at the World Diabetes Day 2020 in Lund (<https://youtu.be/BN-v8KCvxqQ>).

NextCell's strategy is to take ProTrans to market approval for the treatment of type 1 diabetes as soon as possible, which means a continued focus on patients who meet the inclusion criteria in previous studies. In addition, the company supports investigator-initiated trials that aim to make ProTrans a possible treatment for more patients.

“We are very happy and proud that Professor Carlsson and colleagues believe so strongly in ProTrans that they choose to invest their own research grants in this extremely important study. This can be of great importance for the young people of the future who suffer from diabetes”, says Mathias Svahn, CEO of NextCell.

NextCell will contribute ProTrans and placebo in the study. In addition, the company will support with logistics, documentation and expert expertise. No additional monetary compensation is paid.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 16th of October 2020.

For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO

Sofia Fredrikson, CFO

Tel: 08-735 5595

E-mail: info@nextcellpharma.com

Hemsida: www.nextcellpharma.com

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

About NextCell Pharma AB

NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is to take ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Health and Social Care Inspectorate. FNCA Sweden AB is appointed Certified Adviser, +46(0)8-528 00 399, info@fnca.se.